Last reviewed · How we verify
captopril, Losartan (drug)
Captopril and losartan work together to lower blood pressure by inhibiting the renin-angiotensin-aldosterone system through different mechanisms: captopril blocks ACE enzyme while losartan blocks angiotensin II receptor.
Captopril and losartan work together to lower blood pressure by inhibiting the renin-angiotensin-aldosterone system through different mechanisms: captopril blocks ACE enzyme while losartan blocks angiotensin II receptor. Used for Hypertension, Heart failure, Post-myocardial infarction.
At a glance
| Generic name | captopril, Losartan (drug) |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Drug class | ACE inhibitor and angiotensin II receptor antagonist combination |
| Target | ACE enzyme and AT1 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Captopril is an ACE inhibitor that prevents the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Losartan is an angiotensin II receptor antagonist (ARB) that blocks AT1 receptors, preventing angiotensin II from exerting its vasoconstrictive effects. Together, they provide dual blockade of the renin-angiotensin system for enhanced blood pressure reduction.
Approved indications
- Hypertension
- Heart failure
- Post-myocardial infarction
Common side effects
- Cough
- Dizziness
- Hyperkalemia
- Hypotension
- Headache
- Fatigue
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
- Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients (PHASE4)
- Multidiscipline Care for Acute Kidney Disease (AKD) (NA)
- The Canadian Prevention of Renal and Cardiovascular Endpoints Trial (NA)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- captopril, Losartan (drug) CI brief — competitive landscape report
- captopril, Losartan (drug) updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI